Biocom Criticizes New Pharmaceutical Tariffs

Industry group says Section 232 tariffs will hurt US drug supply and innovation.

Apr. 6, 2026 at 5:18pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring an arrangement of glass laboratory beakers and vials on a clean white background, conveying the precision and innovation of the pharmaceutical industry.Precision laboratory equipment symbolizes the pharmaceutical industry's critical role in developing new drugs and treatments.South San Francisco Today

The biotechnology and pharmaceutical industry group Biocom has issued a statement criticizing the Biden administration's decision to impose new Section 232 tariffs on certain pharmaceutical imports. Biocom argues the tariffs will disrupt the US drug supply chain and undermine domestic innovation in the industry.

Why it matters

The pharmaceutical industry is a critical part of the US economy, contributing over $1.2 trillion annually and supporting millions of high-paying jobs. Biocom represents many of the country's leading biotech and drug companies, who say the new tariffs could lead to drug shortages, higher prices for consumers, and reduced investment in R&D.

The details

The Section 232 tariffs, which allow the president to impose duties on imports deemed a threat to national security, will target a range of pharmaceutical ingredients, finished drugs, and medical devices. Biocom says the tariffs will increase costs for US drug makers, who rely on a global supply chain, and ultimately lead to higher prices for patients.

  • The Biden administration announced the new Section 232 pharmaceutical tariffs on April 1, 2026.
  • The tariffs are set to take effect on June 1, 2026.

The players

Biocom

A trade association representing the biotechnology and pharmaceutical industries in California and across the United States.

Got photos? Submit your photos here. ›

What they’re saying

“These tariffs will disrupt the US drug supply chain, increase costs for patients, and undermine our global leadership in pharmaceutical innovation.”

— Joe Panetta, President and CEO of Biocom

What’s next

Biocom says it will continue to advocate against the tariffs and work with the Biden administration to find alternative policies that support the US pharmaceutical industry.

The takeaway

The new Section 232 tariffs on pharmaceuticals highlight the complex tradeoffs between protecting domestic industries and maintaining a globally integrated supply chain. The biotech and drug sectors warn the tariffs could backfire by raising costs, limiting access to critical medicines, and stifling innovation.